Hem/Onc Roundup: Magic Mushrooms Reduced Cancer Distress, Bacteria May Impact Uptick in CRC Cases in Younger Patients, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved the first treatment for epithelioid sarcoma, a study found that “magic mushrooms” help with cancer-related depression and anxiety, and more.

It’s not uncommon for cancer patients to experience anxiety and/or depression. In a follow-up of a 2016 study, researchers found that a one-time dose of psilocybin, in combination with psychotherapy, may provide significant long-term relief for cancer-related psychiatric distress.

Researchers developed a methylation-based circulating free DNA early multi-cancer detection blood test that accurately and simultaneously detected various cancers, including gastrointestinal cancers. The research was presented at the Gastrointestinal Cancers Symposium.

The FDA approved Tazverik™ (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally epithelioid sarcoma who are ineligible for complete resection. This is the first treatment specifically approved for the rare soft-tissue sarcoma that often occurs in young adults.

A study found that the oral bacterium Fusobacterium nucleatum presents in a greater number of colorectal cancer (CRC) tumors among younger patients (diagnosed before age 45 years) compared with older patients. This finding comes as there has been an increase in the number of CRC cases among younger individuals and may point to a difference in the microbiome as a possible reason for this uptick in cancer. The research was presented at the Gastrointestinal Cancers Symposium.

In case you missed it, more hem/onc headlines are featured below: